High Note Wealth LLC Has $878,000 Stock Position in Johnson & Johnson $JNJ

High Note Wealth LLC raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 19.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,750 shares of the company’s stock after purchasing an additional 940 shares during the period. High Note Wealth LLC’s holdings in Johnson & Johnson were worth $878,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Highline Wealth Partners LLC grew its stake in shares of Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after buying an additional 86 shares during the last quarter. Stone House Investment Management LLC bought a new stake in shares of Johnson & Johnson during the first quarter worth $47,000. 1248 Management LLC bought a new stake in shares of Johnson & Johnson during the first quarter worth $48,000. von Borstel & Associates Inc. bought a new stake in shares of Johnson & Johnson during the first quarter worth $49,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in shares of Johnson & Johnson in the first quarter worth $52,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on JNJ shares. Royal Bank Of Canada boosted their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a research note on Thursday, July 17th. Wells Fargo & Company set a $212.00 price objective on shares of Johnson & Johnson and gave the stock an “overweight” rating in a research note on Friday, October 3rd. Citigroup boosted their price objective on shares of Johnson & Johnson from $200.00 to $213.00 and gave the stock a “buy” rating in a research note on Tuesday. Bank of America upped their price target on shares of Johnson & Johnson from $175.00 to $198.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Finally, Erste Group Bank raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $189.88.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 0.5%

JNJ opened at $189.75 on Thursday. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $190.22. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company’s 50-day moving average is $177.49 and its 200 day moving average is $163.37. The firm has a market capitalization of $456.98 billion, a PE ratio of 20.29, a P/E/G ratio of 2.41 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same period in the prior year, the firm earned $2.82 EPS. The company’s revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were issued a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio (DPR) is 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.